Charlotte M C Oude Ophuis1, Alexander C J van Akkooi2, Piotr Rutkowski3, Christiane A Voit4, Joanna Stepniak5, Nicole S Erler6, Alexander M M Eggermont7, Michel W J M Wouters8, Dirk J Grünhagen9, Cornelis Kees Verhoef10. 1. Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: c.oudeophuis@erasmusmc.nl. 2. Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. Electronic address: a.v.akkooi@nki.nl. 3. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland. Electronic address: rutkowskip@coi.waw.pl. 4. Department of Dermatology, Venerology and Allergology, Charité - University, Medicine Berlin, Berlin, Germany. 5. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland. Electronic address: jostepniak@gmail.com. 6. Department of Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands. Electronic address: n.erler@erasmusmc.nl. 7. Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; General Director, Department of Surgical Oncology, Gustave Roussy Cancer Campus Grand Paris, Villejuif/Paris-Sud, France. Electronic address: alexander.eggermont@gustaveroussy.fr. 8. Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands. Electronic address: m.wouters@nki.nl. 9. Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: d.grunhagen@erasmusmc.nl. 10. Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address: c.verhoef@erasmusmc.nl.
Abstract
BACKGROUND: Sentinel node biopsy (SNB) is essential for adequate melanoma staging. Most melanoma guidelines advocate to perform wide local excision and SNB as soon as possible, causing time pressure. OBJECTIVE: To investigate the role of time interval between melanoma diagnosis and SNB on sentinel node (SN) positivity and survival. METHODS: This is a retrospective observational study concerning a cohort of melanoma patients from four European Organization for Research and Treatment of Cancer Melanoma Group tertiary referral centres from 1997 to 2013. A total of 4124 melanoma patients underwent SNB. Patients were selected if date of diagnosis and follow-up (FU) information were available, and SNB was performed in <180 d. A total of 3546 patients were included. Multivariable logistic regression and Cox regression analyses were performed to investigate how baseline characteristics and time interval until SNB are related to positivity rate, disease-free survival (DFS) and melanoma-specific survival (MSS). FINDINGS: Median time interval was 43 d (interquartile range [IQR] 29-60 d), and 705 (19.9%) of 3546 patients had a positive SN. Sentinel node positivity was equal for early surgery (≤43 d) versus late surgery (>43 d): 19.7% versus 20.1% (p = 0.771). Median FU was 50 months (IQR 24-84 months). Sentinel node metastasis (hazard ratio [HR] 3.17, 95% confidence interval [95% CI] 2.53-3.97), ulceration (HR 1.99, 95% CI 1.58-2.51), Breslow thickness (HR 1.06, 95% CI 1.04-1.08), and male gender (HR 1.58, 95% CI 1.26-1.98) (all p < 0.00001) were independently associated with worse MSS and DFS; time interval was not. INTERPRETATION: No effect of time interval between melanoma diagnosis and SNB on 5-year survival or SN positivity rate was found for a time interval of up to 3 months. This information can be used to counsel patients and remove strict time limits from melanoma guidelines.
BACKGROUND: Sentinel node biopsy (SNB) is essential for adequate melanoma staging. Most melanoma guidelines advocate to perform wide local excision and SNB as soon as possible, causing time pressure. OBJECTIVE: To investigate the role of time interval between melanoma diagnosis and SNB on sentinel node (SN) positivity and survival. METHODS: This is a retrospective observational study concerning a cohort of melanomapatients from four European Organization for Research and Treatment of Cancer Melanoma Group tertiary referral centres from 1997 to 2013. A total of 4124 melanomapatients underwent SNB. Patients were selected if date of diagnosis and follow-up (FU) information were available, and SNB was performed in <180 d. A total of 3546 patients were included. Multivariable logistic regression and Cox regression analyses were performed to investigate how baseline characteristics and time interval until SNB are related to positivity rate, disease-free survival (DFS) and melanoma-specific survival (MSS). FINDINGS: Median time interval was 43 d (interquartile range [IQR] 29-60 d), and 705 (19.9%) of 3546 patients had a positive SN. Sentinel node positivity was equal for early surgery (≤43 d) versus late surgery (>43 d): 19.7% versus 20.1% (p = 0.771). Median FU was 50 months (IQR 24-84 months). Sentinel node metastasis (hazard ratio [HR] 3.17, 95% confidence interval [95% CI] 2.53-3.97), ulceration (HR 1.99, 95% CI 1.58-2.51), Breslow thickness (HR 1.06, 95% CI 1.04-1.08), and male gender (HR 1.58, 95% CI 1.26-1.98) (all p < 0.00001) were independently associated with worse MSS and DFS; time interval was not. INTERPRETATION: No effect of time interval between melanoma diagnosis and SNB on 5-year survival or SN positivity rate was found for a time interval of up to 3 months. This information can be used to counsel patients and remove strict time limits from melanoma guidelines.
Authors: Daniel W Nelson; Stacey Stern; David E Elashoff; Robert Elashoff; John F Thompson; Nicola Mozzillo; Omgo E Nieweg; Harald J Hoekstra; Alistair J Cochran; Mark B Faries Journal: J Am Coll Surg Date: 2017-06-28 Impact factor: 6.113
Authors: D Evrard; E Routier; C Mateus; G Tomasic; J Lombroso; F Kolb; C Robert; A Moya-Plana Journal: Eur Arch Otorhinolaryngol Date: 2018-03-19 Impact factor: 2.503
Authors: Evalyn E A P Mulder; Iva Johansson; Dirk J Grünhagen; Dennie Tempel; Barbara Rentroia-Pacheco; Jvalini T Dwarkasing; Daniëlle Verver; Antien L Mooyaart; Astrid A M van der Veldt; Marlies Wakkee; Tamar E C Nijsten; Cornelis Verhoef; Jan Mattsson; Lars Ny; Loes M Hollestein; Roger Olofsson Bagge Journal: Cancers (Basel) Date: 2022-06-09 Impact factor: 6.575
Authors: Mary-Ann El Sharouni; Paul Johannes van Diest; Arjen Joost Witkamp; Vigfús Sigurdsson; Carla Henrica van Gils Journal: JNCI Cancer Spectr Date: 2020-10-23
Authors: D Verver; D van Klaveren; V Franke; A C J van Akkooi; P Rutkowski; U Keilholz; A M M Eggermont; T Nijsten; D J Grünhagen; C Verhoef Journal: Br J Surg Date: 2018-10-11 Impact factor: 6.939
Authors: E E A P Mulder; J T Dwarkasing; D Tempel; A van der Spek; L Bosman; D Verver; A L Mooyaart; A A M van der Veldt; C Verhoef; T E C Nijsten; D J Grunhagen; L M Hollestein Journal: Br J Dermatol Date: 2020-11-02 Impact factor: 9.302